Stockreport

Genentech’s Giredestrant Reduced Risk of Invasive Disease Recurrence or Death by 30% in ER-positive Early-Stage Breast Cancer

ROCHE HOLDING LTD S/ADR  (RHHBY) 
NASDAQ:AMEX Investor Relations: roche.com/investors.htm
PDF – Giredestrant is the only oral SERD to show superior invasive disease-free survival in the adjuvant setting, marking the first significant endocrine therapy advance in [Read more]